@mcuban.bsky.social recently brought his business expertise to #StanDOM's Grand Rounds β diagnosing the American healthcare system & proposing a treatment plan.
Watch the full video & read the key takeaways: stanford.io/3FbkfZr
@funchainmd.bsky.social
Melanoma oncology @Stanford. Study hereditary genetics and irAEs. LA explant in SF via Ohio State, NIH/NHGRI, Harbor UCLA, and Cleveland Clinic. Sports fan, geek and mom. APD Hem/Onc fellowship. ASPirE founder, Checkpoint Now. COI http://bit.ly/43UCDOz
@mcuban.bsky.social recently brought his business expertise to #StanDOM's Grand Rounds β diagnosing the American healthcare system & proposing a treatment plan.
Watch the full video & read the key takeaways: stanford.io/3FbkfZr
This program reflects our commitment to fostering meaningful partnerships and supporting the next generation of leaders in cancer research. Weβre proud to be part of their journey and look forward to the ideas and energy they bring to our community this summer. @funchainmd.bsky.social
11.06.2025 21:06 β π 4 π 1 π¬ 0 π 0Wrapping up #ASCO24 with this thought: letβs get more people under the survival curve and lift it up - it might be prolonged survival, it might even be cure. Every moment counts.
May we all walk into our post ASCO lives inspired β¨ π @ascocancer.bsky.social @aspire-cop.bsky.social
Melanoma orals #9 β‘οΈ DANTE trial in 1L metastatic melanoma comparing 1 vs 2 yr anti PD1 + anti CTLA4
β‘οΈ obstacles to accrual, underpowered, stopping at 1 year non inferior*
β‘οΈ no difference in QOL but less concern with staying on treatment
Sarah Danson U Sheffield #ASCO25 @ascocancer.bsky.social
Melanoma orals #8 β‘οΈ S2000 enco bini nivo vs ipi nivo in symptomatic melanoma brain mets
β‘οΈFirst randomized trial in symptomatic brain mets
β‘οΈSignificant PFS improvement with triple therapy over ipi nivo
β‘οΈNo significant OS benefit
Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social
Melanoma orals #7 β‘οΈ 5 year overall survival from DREAMSEQ
β‘οΈ 63.3% for ipi/nivo first
β‘οΈ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
Melanoma orals #7 β‘οΈ 5 year overall survival from DREAMSEQ
β‘οΈ 63.3% for ipi/nivo first
β‘οΈ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
Melanoma orals #6 β‘οΈ ECOG 6194 ph II pembro + injectable TLR9 agonist vidutolimod in stage III melanoma
pCR 71% MPR 79% 1 yr EFS 89%
Me: pCR much higher than other studies but with an injectable agent very hard to interpret the systemic effect
Ahmad Tarhini #ASCO25 @ascocancer.bsky.social
Melanoma orals #4 β‘οΈ ph
II neoadjuvant dostarlimab + anti TIM3 cobolimab in stage III melanoma
D+C with mPR 51.9% with 1 yr EFS 92%
Megan Mooradian @mgbresearch.bsky.social #ASCO25 @ascocancer.bsky.social
Melanoma orals #4 β‘οΈ ph II neadjuvant anti TIGIT tiragolimab and atezolizumab in stage III melanoma
β‘οΈ47.7% pCR
β‘οΈ91.7% 12 m RFS for those with MPR
β‘οΈno type 1 DM, AI
Tina Heiken @mayocliniccancer.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
Caroline Robert asks if we should move away from CTCAE grading of irAE in trials and acknowledge the AI (which she notes is more likely focal hypopit rather than AI) is actually a 6% rate of permanent medication-requiring disease #irAE #ASCO25 #melsm @ascocancer.bsky.social @aspire-cop.bsky.social
03.06.2025 15:46 β π 2 π 0 π¬ 0 π 0Discussion of 1st set of melanoma orals by Ana Arance - Toxicities are the *key* challenge in the adjuvant setting and mitigation of #irAE are the priority in this setting #ASCO25
@ascocancer.bsky.social @aspire-cop.bsky.social
Melanoma orals #3 β‘οΈ neoadjuvant pembro on stage II/III melanoma
Stage IIC SLN positivity significantly different from historical controls; 2 yr RFS βhighβ
Me: Intriguing but hard to understand if true impact given a (moving) historical control
Georgios Karakousis
#ASCO25 @ascocancer.bsky.social
Melanoma oral #2 #ASCO25
Ph III adjuvant enco bini - Alex van Akkooi summarizes as a tolerable regimen
@ascocancer.bsky.social
Melanoma oral #1 #ASCO25 β‘οΈ ph III adj rela nivo vs nivo (RELATIVITY 098) - no difference in RFS, DMFS
Presented by Georgina Long @melanomaau.bsky.social @ascocancer.bsky.social
Actually, yes, this and a fantastic set of encyclopedias
02.06.2025 23:19 β π 23505 π 2570 π¬ 731 π 273Seeing this picture gave me joy - thank you for being a light in our community! π
03.06.2025 14:23 β π 1 π 0 π¬ 0 π 0Amazing to meet my fellow β¨Featured Voiceβ¨ Dr @funchainmd.bsky.social at the #WLO event. Best on your presentation today! βͺ@aspire-cop.bsky.socialβ¬ #ASPIRE #ASCO25 #HeForShe π #SuppOncSelfiesπΈ
@kmittalmd.bsky.social
@ascocancer.bsky.social
@oncodaily.bsky.social
Where are TIL today, one year later? #ASCO25
β‘οΈ4 year OS 22.2%
β‘οΈfront line with excellent ORR, although 12 month survival lower than checkpoint inhibition
β‘οΈin real practice, multiple paths to, off, and after TIL for individual patients
Don Lawrence @mgbresearch.bsky.social @ascocancer.bsky.social
Multiple new agents with mechanisms other than immunotherapies under investigation for metastatic melanoma:
β‘οΈ new BRAF targeting agents
β‘οΈ PRMT5 inhibition
β‘οΈ ROR2 ADC
-Meredith McKean, Sarah Cannon
#ASCO25 @ascocancer.bsky.social
AI imaging of skin cancer has good prediction but predictive power dropped in a larger pretesting dataset - important to check AI algorithms at multiple time points!
Susan Swetter @stanford-cancer.bsky.social #ASCO25 @ascocancer.bsky.social
JAMA Oncology is now on @bsky.app !!
Follow @jamaoncology.bsky.social & @jama.com for oncology content #MedSky #OncSky #ASCO25
Much less clarity on whether or not to continue systemic immunotherapy after pCR following neoadjuvant therapy
The people have spoken, and they are undedecided - more work to do! #melsm #ASCO25
Ever wonder how pathologists calculate neoadjuvant response metrics (% residual viable tumor, % necrosis, % regression)? Formulas and recommendations for standardized reporting π
Janis Taube @hopkinsmedicine.bsky.social #ASCO25 #melsm @ascocancer.bsky.social
Neoadj ipi/nivo is clear winner in melanoma, prompting Genevieve Boland and Diwakar Davar to discuss the CONSTANT communication required between med onc/ surg onc (and relevant subspecialists) perioperatively to address ir-AI or colitis #ASCO25 #irAE @ascocancer.bsky.social @aspire-cop.bsky.social
02.06.2025 18:44 β π 4 π 1 π¬ 0 π 0Melanoma rapid oral #9 β‘οΈ OBX-115, engineered TIL with membrane bound IL15 regulated with acetazolamide
-for 6pt receiving RP2D, 67% ORR, 1 CR, 100% DCR
-mDOR not reached
Jason Chesney U Louisville and @drbetofmdphd.bsky.social @stanford-cancer.bsky.social
#ASCO25 @ascocancer.bsky.social
Melanoma rapid oral #8 β‘οΈ TIL product characteristics (cell types) that may predict outcome
Me: Would be great to access a profile that saves patients from high toxicity profile but honestly would be hard to lose options
Lilit Karapetyan @moffittnews.bsky.social #ASCO25 @ascocancer.bsky.social
Rapid melanoma oral #7 β‘οΈ 5 year outcomes with lifileucel
-mDOR 36.5m
-31.3% of responders with sustained response
-3 pts with PR that deepened after about a year
-AEs within first 3 m and drop off dramatically
Theresa Medina U Colo
#ASCO25 @ascocancer.bsky.social
Melanoma rapid oral #6 β‘οΈ neoadj lenvatinib + pembro in Merkel cell
-57.7% pCR
-50% at least 1 TRAE
Thoughts - what are we gaining and at what cost? Will be interesting to see long term outcomes given MCC with higher rate of recurrence after CR from IO in stage IV
#ASCO25 @ascocancer.bsky.social
Melanoma rapid orals #5 β‘οΈ single dose of neoadj ipi 3 + nivo 1 with 59% major pathological response and 9% grade 3+ TRAE. CD8 PET not predictive.
Sarah Lochrin @mskcc.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social